ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
February 12 2020 - 09:00AM
Business Wire
ACADIA to Host Conference Call and Webcast on
Wednesday, February 26, 2020, at 5:00 p.m. Eastern Time
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it will report fourth quarter and full year 2019 financial results
on Wednesday, February 26, 2020, after the close of the U.S.
financial markets. ACADIA’s management team will also host a
conference call and webcast on February 26, 2020, at 5:00 p.m.
Eastern Time to discuss financial results and operations.
The conference call may be accessed by dialing 855-638-4820 for
participants in the United States or Canada and 443-877-4067 for
international callers (reference passcode 6692587). A telephone
replay of the conference call may be accessed through March 11,
2020 by dialing 855-859-2056 for callers in the United States or
Canada and 404-537-3406 for international callers (reference
passcode 6692587). The conference call also will be webcast live on
ACADIA’s website, www.acadia-pharm.com under the investors section
and will be archived there until March 26, 2020.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has
developed and commercialized the first and only medicine approved
for the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. ACADIA also has ongoing clinical
development efforts in additional areas with significant unmet
need, including dementia-related psychosis, major depressive
disorder, the negative symptoms of schizophrenia, and Rett
syndrome. This press release and further information about ACADIA
can be found at: www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to ACADIA’s annual report
on Form 10-K for the year ended December 31, 2018 as well as
ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200212005181/en/
Media Contact: ACADIA Pharmaceuticals Inc. Stephanie Fagan (858)
212-0534 media@acadia-pharm.com
Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2023 to Mar 2024